Eupraxia Pharmaceuticals Inc.
EPRX
Positions held
Your positionsEPRX isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $500.18M | Enterprise value | $395.02M | Trailing P/E | — | Forward P/E | -7.30 |
| PEG | — | Price / book | 4.87 | Beta | 1.22 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -66.7% | ROA | -43.7% | Debt / equity | 0.01 |
| Current ratio | 16.00 | Free cash flow | -$18.93M | Analyst recommendation | strong_buy | Mean target | $16.35 |
| 52w high | $9.32 | 52w low | $5.25 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$14.5M | -$12.7M | -$16.7M | -$6.4M | -$8.7M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$18.1M | -$16.0M | -$16.2M | -$6.9M | -$8.3M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$38.6M | -$25.5M | -$28.2M | -$18.5M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$38.4M | -$27.0M | -$27.8M | -$17.6M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-30 · Eupraxia Says Resolve Trial Updated Data Suggest Annual Dosing Possible in EoE Patients
2026-09-24 · Wedbush Initiates Eupraxia Pharmaceuticals at Outperform With $17 Price Target
2026-09-12 · Eupraxia Pharma (EPRX): When Painful Swallowing Nearly Disappeared, Investors Took Notice
2026-08-11 · Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results
2026-07-28 · Top Premarket Decliners
2026-07-13 · Eupraxia Pharmaceuticals Announces Executive Leadership Changes
2026-07-13 · Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth
Price (daily)
Full chart · RSI · MACD · patterns